by Rod Raynovich | Nov 5, 2010 | BIOgraph
Cardiovascular Systems(CSII) is a medical device Company that focuses on interventional treatment for peripheral arterial disease(PAD). The primary products are the Diamondback 360 and the Predator 360, minimally invasive catheter systems for a range of plaque types...
by Rod Raynovich | Oct 29, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Abaxis (ABAX) beat estimates with reported Q3 Revenues of $35.3M/$0.17 up 17% over last year’s comparable quarter. Cash position is $100.6M up from $87.6M last year’s Q3. March ’11 Fiscal Year estimates are $143M and $0.72/sh. Shares are up 0.97%...
by Rod Raynovich | Oct 28, 2010 | BIOgraph
EXAS -Big Sell-Off on the News Exact Sciences (EXAS) was down 20% today after presenting its first validation data on the performance of its experimental, non-invasive colorectal cancer test. As of midday trading the stock was around $6.90 on huge volume over 5.5 M...
by Rod Raynovich | Oct 27, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Timing is everything and Pacific Biosciences(PACB) took advantage of a good year for biotech stocks, better earnings for tools and Dx companies and a rebounding IPO market. Pacific Biosciences raised $200M($16) at the midpoint of the expected range and shares advanced...
by Rod Raynovich | Oct 22, 2010 | BIOgraph
GE announced the purchase of Clarient (CLRT) for $5/share or $580M, a 34% premium over Clarient’s previous closing price. Revenues forecasted for 2011 and 2012 are at $114M and $136M respectively, pricing the deal at a Price to Sales of 4.25 to 5X. Revenues for...
by Rod Raynovich | Oct 20, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Risk is on today due to a weak dollar and that is usually good for Life Science stocks.MidCap biotechs are mainly green despite bad news from Amylin (AMLN) $11.35 down 44%, and partner Alkermes (ALKS) $10.91 down 24.75% a setback on their long- acting drug for...
by Rod Raynovich | Oct 15, 2010 | BIOgraph
The Rayno Life Science Portfolio is up 20% and later this month we will see important earnings reports from tools and diagnostics companies. Life Science stocks are outperforming the NASDAQ and S&P in 2010. Exact Sciences(EXAS) $8.89 was a high flier for Q3 with...
by Rod Raynovich | Oct 6, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Stock is down over 18% at 3p near $16.5 on 7M shares A “Pure Play “Immunohematology Diagnostic Company Immucor announced Fiscal Q1 2011 results yesterday with a revenue shortfall of (9%) on traditional reagents $49.621M vs $54.719M in Fiscal 2010. Total...
by Rod Raynovich | Oct 5, 2010 | 2024-25 Life Science Portfolios, BIOgraph
2010 Original Price % Ret. P Price % Recomm 3/29/10 Q2 12/1/10 Ret. Abaxis ABAX 2/2/09 15 79 21.2 27.86 85 CardioV.Sys. CSII 11/5/10 7.15 8.65 21 Celera CRA 3/28/10 7 6.49 5.66 -19 GenProbe GPRO 2/2/09 45 7 46.3 52.77 17 Illumina ILMN 2/2/09 29 35 43.1 61.79 113...
by Rod Raynovich | Oct 4, 2010 | 2024-25 Life Science Portfolios, BIOgraph
2010 Price Original P Price % Ret 7/2/10 Recomm 12/1/10 Alexion ALXN 50.45 2/2/09 35 76.24 117 Ardea Biosci RDEA 19.5 2/2/09 12 22.26 85 Amgen AMGN 51.7 2/2/09 55 53.52 -5 Biogen BIIB 49.42 2/2/09 49 65.37 33 Cephalon CEPH 55.95 2/2/09 77 64.26 -16.5 Cubist CBST 20.7...
